Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $24.9 million, up 25% year over year
- ➤Full-year 2026 revenue guidance raised to $92 million-$93 million
- ➤Interventional Dry Eye Q3 revenue $3.9 million, up from $0.2 million
- ➤Net loss narrowed 17% to $6.8 million; loss per share $0.12
- ➤Cash usage fell 74% year over year to $2.4 million
Expert Statements
Paul Badawi, Co-Founder and CEO of Sight Sciences
“We delivered another strong quarter with 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash burn. These results demonstrate increasing adoption of our technologies, disciplined execution across our organization, and our growing impact on patients with glaucoma and dry eye disease”
Paul Badawi, Co-Founder and CEO of Sight Sciences
“With IG strengthening our foundation and IDE rapidly developing into a meaningful growth driver, we are demonstrating the strength of our interventional eye care platform and the significant opportunity ahead. We remain focused on expanding the adoption of our technologies and advancing interventional eye care for the customers and patients we serve.”
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2026.
Recent Financial and Business Highlights * Record revenue of $24.9 million in the third quarter of 2026, a 25% increase compared to $19.9 million in the third quarter of 2025.
Get started
Create a free account to read the full story.